<DOC>
	<DOCNO>NCT01830816</DOCNO>
	<brief_summary>This phase 1/1b , open-label , multicenter study oral ixazomib ( MLN9708 ) design assess pharmacokinetics ( PK ) single dose ixazomib patient normal renal function patient severe renal impairment ( RI ) ( accord Cockcroft-Gault estimate ) . Twenty-eight PK-evaluable patient enrol either 1 2 arm study . Arm 1 : ( N = 12 ) : Normal renal function ( creatinine clearance [ CrCl ] ≥ 90 mL/min ) Arm 2 : ( N = 16 ) : Severe RI ( CrCl &lt; 30 mL/min ) include least 6 patient ESRD , define renal failure require hemodialysis</brief_summary>
	<brief_title>Pharmacokinetics Study Oral Ixazomib ( MLN9708 ) Relapsed/Refractory Multiple Myeloma Advanced Solid Tumors Patients With Normal Renal Function Severe Renal Impairment</brief_title>
	<detailed_description />
	<mesh_term>Multiple Myeloma</mesh_term>
	<mesh_term>Neoplasms , Plasma Cell</mesh_term>
	<mesh_term>Renal Insufficiency</mesh_term>
	<mesh_term>Ixazomib</mesh_term>
	<mesh_term>Glycine</mesh_term>
	<criteria>Male female patient 18 year old Patients multiple myeloma ( MM ) diagnose accord standard criterion patient diagnosis advance malignant solid tumor standard , curative , life prolong treatment exist longer effective . Patients multiple myeloma must least 1 prior therapy Patients relapsed/refractory multiple myeloma least 1 prior therapy A calculate creatinine clearance ( CrCl ) meet entry criterion enrollment ( ie , calculate CrCl either ≥ 90 &lt; 30 mL/min Eastern Cooperative Oncology Group ( ECOG ) performance status 0 , 1 , 2 Female patient post menopausal , surgically sterile , agree practice 2 effective method contraception 90 day last dose study drug agree practice true abstinence Male patient agree practice effective barrier contraception 90 last dose study drug agree practice true abstinence Voluntary write informed consent Suitable venous access Female patient pregnant lactate breastfeeding Failure recover clinically significant effect prior chemotherapy ( define toxicity great Grade 1 exception alopecia ) Major surgery radiotherapy within 14 day study drug administration Dexamethasone ( equivalent systemic steroid ) high physiologic dose 7 day study drug administration Central nervous system involvement Infection require IV antibiotic therapy serious infection within 14 day prior first dose study drug Diagnosis Waldenstrom 's macroglobulinemia , POEMS ( polyneuropathy , organomegaly , endocrinopathy , monoclonal gammopathy , skin change ) syndrome , plasma cell leukemia , myeloproliferative syndrome , primary amyloidosis ( exception patient amyloidosis document complication MM , evaluate casebycase basis trial participation ) Systemic treatment strong moderate inhibitor CYP1A2 , strong moderate inhibitor CYP3A , clinically significant CYP3A inducer use Ginkgo biloba St. John 's wort within 14 day first dose study drug Evidence uncontrolled cardiovascular condition Ongoing active infection , know human immunodeficiency virus ( HIV ) positive Comorbid systemic illness psychiatric illness could interfere study completion Known allergy study medication Inability swallow oral medication condition could interfere oral absorption tolerance treatment</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>Relapsed</keyword>
	<keyword>Refractory</keyword>
	<keyword>Multiple Myeloma</keyword>
	<keyword>Advanced solid tumor</keyword>
</DOC>